

Posaconazole

Reserve Antimicrobial See CUH Antimicrobial Guidelines on Eolas for further information		
CAUTION: High Administration Risk Rating		
CAUTION: Posaconazole may be administered as a loading dose followed by a maintenance dose . Double check the correct dose has been prescribed.		
Form & Storage	300mg in 16.7ml	Vials should be stored in a fridge (2°C-8°C)
Reconstitution	Already in solution	
Compatibility and Stability	Sodium chloride 0.9% Glucose 5%	
Administration	IV Infusion only Add 16.7ml of posaconazole solution to 250ml of compatible infusion fluid and administer over 90 minutes via a central line or PICC. Concentration range 1-2mg/ml Note: If a central line is unavailable a <u>single</u> infusion can be given peripherally via a large vein: Add 16.7ml of posaconazole solution to 133ml of compatible infusion fluid (by removing 117ml from a 250ml bag) and administer over 30 minutes (concentration 2mg/ml) Note: In clinical studies, multiple peripheral infusions given through the same vein resulted in infusion site reactions Review to switch to oral route of administration as soon as the patient's condition allows. Consult Eolas for dosing-tablets and liquid available. Note: oral formulations are not interchangeable	
Extravasation	Extravasation may cause tissue damage due to a low pH	
Monitor	ECG, liver function, renal function, electrolytes, infusion site	
Additional Information Adverse Drug Reactions	<ul style="list-style-type: none"> Posaconazole is usually prescribed as a loading dose 300mg BD (first 24 hours) followed by a maintenance dose 300mg OD (after first 24 hours) Never administer posaconazole as an IV bolus Posaconazole given peripherally can result in infusion site reactions/phlebitis, monitor site of injection Adverse effects include: fever, arrhythmias, thrombosis, infusion site reactions, hypersensitivity and allergic reactions The excipient betadex sulfobutyl ether sodium may accumulate in patients with moderate to severe renal impairment (eGFR <50ml/min). Monitor renal function and review route of administration regularly 	

Information provided relates to Noxafil (MSD)